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Background: MicroRNAs (miRNAs) emerge as new important regulators of lipid homeostasis by regulating
corresponding genes. MiR-613 is a newly discovered microRNA, of which the biological function is unknown.
A recent report has shown that miR-613 downregulates liver X receptor α (LXRα), a ligand-activated nuclear
receptor playing an important role in the regulation of lipid metabolism. The purpose of this study is to explore
the effect and the molecular basis of miR-613 on lipogenesis in HepG2 cells.
Methods: HepG2 cells were transiently transfected with miR-613 mimic or control microRNA. Real time PCR,
Western blot, Luciferase reporter assay and Oil Red O staining were employed to examine the expression of LXRα
and its target genes involved in lipogenesis, binding site for miR-613 in 30-untranslated region (30-UTR) of LXRα
mRNA and lipid droplet accumulation in the cells.
Results: MiR-613 dramatically suppressed the expression of LXRα and its target genes including sterol-regulatory
element binding protein 1c (SREBP-1c), fatty acid synthase (FAS), carbohydrate responsive element-binding protein
(ChREBP) and acetyl-CoA carboxylase (ACC). Reporter assay showed that miR-613 directly bound to 30-UTR of LXRα
mRNA. Moreover, miR-613 significantly repressed LXRα-induced lipid droplet accumulation in HepG2 cells. Ectopic
expression of LXRα without 30-UTR markedly attenuated the miR-613-mediated downregulation of LXRα’s target
genes and LXRα-induced lipid droplet accumulation.
Conclusions: MiR-613 suppresses lipogenesis by directly targeting LXRα in HepG2 cells, suggesting that miR-613
may serve as a novel target for regulating lipid homeostasis.
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MicroRNAs (miRNAs) are a class of 22 nucleotide
non-coding RNAs that regulate genes by binding to the
30-untranslated region (30-UTR) of target mRNAs. They
are implicated in a variety of diseases including obesity,
cancer, atherosclerosis and diabetes [1-3]. Recent studies
have shown that miRNAs play an important role in lipid
metabolism and several miRNAs have been identified,
such as miR-33, miR-122, miR-27, miR-370 [4,5]. MiR-33
regulates the ATP-binding cassette transporters (ABC trans-
porters), ABCA1 and ABCG1, in addition to its role in fatty
acid β-oxidation. MiR-122 regulates several genes that* Correspondence: cqhuanggang@yahoo.com.cn; hefengtian06@yahoo.com.
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reproduction in any medium, provided the orcontrol fatty acid (FA) and Triglyceride (TG) biosynthesis,
such as fatty acid synthase (FAS), acetyl-CoA carboxylase 1
(ACC-1), acetyl-CoA carboxylase 2 (ACC-2), and sterol
regulatory element-binding protein 1c (SREBP-1c), as
well as genes that regulate fatty acid β-oxidation, such
as carnitine palmitoyltransferase 1α (CPT1α) [6]. Similarly,
other miRNAs regulate lipid homeostasis by targeting a
variety of lipid metabolism–associated genes.
MiR-613 is a newly discovered miRNA, whose func-
tion and molecular basis in the biological process and
diseases is incompletely understood. It is reported that
miR-613 plays inhibitory role in repressing the Wnt
pathway, but its effect on the Wnt-dependent biological
processes is unclear. Another report demonstrates the
negative role of miR-613 in a feedback loop in the auto-
regulation of the human LXRα [7,8] without showing itsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Primers used for PCR
Primer name Sequence
LXRα 30-UTR Forward 50-CTGTTCTGTCCCCATATTTTCTG-30
LXRα 30-UTR Reverse 50-TCGCAACCCTTTGACTCTCT-30
LXRβ 30-UTR Forward 50-GACCACCCTCCAGCAGATAG-30
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the biological function of miR-613 in future.
Lipid homeostasis is regulated by a family of transcrip-
tion factors including the nuclear hormone receptor
LXRα [9]. The molecular mechanism responsible for
LXRα-mediated lipogenesis has been largely attributed
to the dramatic upregulation of the lipogenic genes such as
SREBP-1c, FAS, ChREBP and ACC [10-14]. LXRα-induced
activation of those genes can result in the enhancement of
fatty acid synthesis, which contributes to a series of
lipogenesis-associated diseases. Therefore, since miR-613
directly targets and decreases the expression of LXRα, fur-
ther studies are needed to determine whether miR-613 can
relief LXRα-induced lipogenesis via repression of LXRα
expression.
In this study, we confirmed that miR-613 directly
downregulated LXRα expression at both mRNA and pro-
tein levels. Subsequently, LXRα-induced lipogenic genes,
such as SREBP-1c, FAS, ChREBP and ACC, were inhibited
by miR-613, which was abolished by the ectopic expres-
sion of LXRα without 30-UTR. Oil Red O staining revealed
that miR-613 reduced LXRα-induced lipid droplet accu-
mulation in HepG2 cells, which was also attenuated by ec-
topic expression of LXRα. Our study suggests miR-613 as
a critical regulator of lipogenesis.
Materials and methods
Reagents
The miR-613 mimic (50- AGGAAUGUUCCUUCUUU
GCC -30) and negative control (NC, 50- UUCUCCGA
ACGUGUCACGUTT -30) were synthesized by Shanghai
GenePharma (Shanghai, China). TO901317 and GW3965
were purchased from Sigma Chemical Company (St Louis,
MO, USA)
Cell culture
Human hepatocellular carcinoma cell line HepG2 was
purchased from ATCC and cultured in Dulbeco’s Modified
Eagle’s medium (Gibco, Shanghai, China) supplemented
with 10% fetal bovine serum (FBS) (Gibco, Gaithersburg,
USA), streptomycin (100 μg/ml) and antibiotics (100 U/ml
penicillin and 100 μg/ml streptomycin) at 37°C in 5% CO2
humid incubator.
Plasmid construction
The DNA fragment corresponding to 76-113 nt of hu-
man LXRα 30-UTR containing the miR-613 binding site
was synthesized by Sangon Biotech and cloned into
pMIR-REPORT vector (Invitrogen) at Sac I and Hind III
site downstream of the luciferase gene, and the resulting plas-
mid was named as pMIR/LXRαMIRE. Similarly, the DNA
fragment containing mutations in miR-613 binding site was
synthesized and cloned into pMIR-REPORT, and the
resulting plasmid was named as pMIR/LXRαMIRE–mut.The 30-UTR of the human LXRβ gene was amplified by PCR
with the cDNA of HepG2 cells as template. Purified PCR
products digested by Sac I and Hind III (Takara) were cloned
into pMIR-REPORT vector, and the resulting plasmid was
named as pMIR-LXRβ.
Transient transfections and luciferase assays
HepG2 cells, grown to 70% to 80% confluence, were transi-
ently transfected with luciferase reporters (pMIR-REPORT,
pMIR-LXRβ, pMIR/LXRαMIRE, pMIR/LXRαMIRE–mut)
and miR-613 mimic or mimic NC, using Lipofectamine 2000
according to the manufacturer’s instructions (Invitrogen).
Transfection efficiency was monitored by cotransfection of
pMIR-REPORT-β-gal (Promega). Luciferase activities were
measured using a luciferase assay system (Promega). Trans-
fection experiments were performed 3 times in triplicate.
Data was represented as fold induction over reporter gene
treated with vehicle alone.
Western blot
24 hours after transfection, cells were exposed to
TO901317 (5 μM) for 24 hours. Dimethyl sulfoxide
(DMSO, Sigma) was used as controls. Then the whole cell
proteins were harvested in lysis buffer (50 mM Tris-base,
150 mM NaCl, 1.0 mM EDTA, 0.1% SDS, 1% sodium
deoxycholate and 1% TritonX-100) containing protease in-
hibitor cocktail. And the protein concentrations were deter-
mined using Bradford protein assay reagent (Bio-Rad).
Subsequently, the total proteins (40 μg/well) were sepa-
rated with 10% SDS-PAGE and transferred to PVDF
(polyvinylidene fluoride) membranes (Millipore). After
blocked 1 hour with 5% nonfat milk, the membranes were
Figure 1 MiR-613 decreases LXRα expression at both mRNA and protein levels. A: HepG2 cells were transfected with 80 nM miR-613 mimic
or mimic negative control (NC), after 24 hours total protein was subjected to Western blotting analysis and mRNA expression levels of LXRα were
analyzed by real-time quantitative PCR and normalized with β-actin control. B and D, HepG2 cells were treated with TO901317 (5 μM) or GW3965
(2 μM) for 24 hours. Western blot analysis for LXRα protein level (B) and Real-time PCR analysis for LXRα mRNA level (D). C and E, 12 hours after
transfected with 80 nM miR-613 mimic or NC, HepG2 cells were treated with TO901317 (5 μM) or GW3965 (2 μM) for 24 hours. Western blot
analysis for LXRα protein level (C) and Real-time PCR analysis for LXRα mRNA level (E). The relative level of LXRα expression determined using the
2-△△CT method. *, P < 0.05 (n = 3 for each group).
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(Abcam), or mouse anti-human β-actin antibody (Santa
Cruz Biotechnology) at 4°C over night. After washing with
TBST, blots were incubated with HRP-labeled rabbit anti-
mouse IgG (Invitrogen) for 1 hour at room temperature.
Detection was achieved using enhanced chemilumines-
cence reagents (Pierce) and exposure to film.Real-time quantitative reverse transcription-polymerase
chain reaction (qRT-PCR)
For qRT-PCR, total RNA was extracted from the HepG2
cells using TRIzol and the first-strand cDNA was synthe-
sized using M-MLV reverse transcriptase (Invitrogen) and
oligo (dT) primer according to the manufacturer’s manual.
The expression of LXRα, SREBP-1c, FAS, ChREBP andACC mRNA was examined by qPCR using SYBR green-
based assays. Relative expressions were calculated with
normalization to β-actin values by using the 2-△△Ct method.
The sequences of primers used for quantitative PCR ana-
lysis were shown in Table 1.Oil Red O staining
Oil Red O stock solution was prepared in isopropanol
(0.25 g/100 ml) and heated to 100°C for 10 min.
TO901317-treated cells were fixed with 4% paraformalde-
hyde for 30 min and washed with PBS. Then cells were
soaked in 60% Oil Red O stock solution diluted by distilled
water for 30 min. Stained cells were washed with PBS until
the background became clear. Images were captured with
fluorescence microscopy (Olympus).
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All data are expressed as means ± SD unless otherwise
stated. Comparisons between two groups were made with
unpaired Student’s t-tests. Non-parametric comparisons
between three or more groups were made with ANOVA
followed by Kruskal–Wallis post hoc analysis. In all cases,
P < 0.05 was considered statistically significant.
Results
MiR-613 reduces LXRα expression at both mRNA and
protein levels
It has been reported that miR-613 negatively regulated
the expression and activity of endogenous LXRα. To
examine whether these results are obtainable under our
experimental conditions, HepG2 cells were transfected
with miR-613 mimic or negative control (NC). Western
blot and real-time PCR analysis showed that endogenous
LXRα expression was repressed by miR-613 at both pro-
tein and mRNA levels (Figure 1A), while LXRβ expres-
sion was not affected, which suggested that miR-613
effect was specific for LXRα. Furthermore, as LXRα acti-
vation leads to the lipogenesis in liver, we determined
whether miR-613 could inhibit agonist-induced LXRαFigure 2 MiR-613 directly targets LXRα 30-UTR. A: A putative binding si
residues are shown in red and italics. B: pMIR/LXRαMIRE or pMIR/LXRαMIRE
cells. C, pMIR-LXRβ was transiently cotransfected with 80 nM indicated RNA
after 24 hours. The data was the firefly luciferase activities normalized withexpression. Treatment with either TO901317 or GW3965
induced mRNA and protein expression of LXRα (Figure 1B
and D), which was repressed by miR-613 (Figure 1C and E).
Similarly, miR-613 suppressed TO901317-induced LXRα
expression at both mRNA and protein levels in L02 cells
(Additional file 1: Figure S1). These results demonstrated
that miR-613 downregulated both endogenous and
agonist-induced LXRα expression.MiR-613 directly targets LXRα 30-UTR
We also found the binding site for miR-613 on LXRα
30-UTR by TargetScan analyses (Figure 2A). Cotransfection
with miR-613 mimic resulted in a decrease of the luciferase
activity of pMIR/LXRαMIRE plasmid containing the
LXRαMIRE613, while the luciferase activity of pMIR/
LXRαMIRE-mut plasmid containing mutations in miR-613
recognition site was not affected (Figure 2B). Moreover,
cotransfection with miR-613 mimic had no effect on the
luciferase activity of pMIR-LXRβ plasmid containing the
LXRβ 30-UTR (Figure 2C). These results revealed that
miR-613 directly targeted LXRα on its 30-UTR, but not
LXRβ.te of miR-613 in the 30-UTR of LXRα mRNA and mutated nucleotide
-mut was cotransfected with 80 nM miR-613 mimic or NC into HepG2
oligonucleotides into HepG2 cells. Luciferase assay was conducted
the β-galactosidase activities. *, P < 0.05 (n = 3 for each group).
Figure 3 MiR-613 suppresses LXRα-induced lipogenic genes. A and B: HepG2 cells were treated with TO901317 (5 μM) or GW3965 (2 μM) for
24 hours. Real-time PCR analysis for SREBP-1c, FAS, ChREBP and ACC mRNA level. C and D, after 12 hours transfected with 80 nM miR-613 mimic
or NC, HepG2 cells were treated with TO901317 (5 μM) or GW3965 (2 μM) for 24 hours. Real-time PCR analysis for SREBP-1c, FAS, ChREBP and
ACC mRNA level. The relative level of lipogenic gene expression determined using the 2-△△CT method. *, P < 0.05 (n = 3 for each group).
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downregulation of LXRα
Activation of LXRα has been shown to promote the hepatic
lipogenesis by increasing the expression of lipogenic genes.
We therefore determined the effect of miR-613 on LXRα-
induced genes related with lipogenesis. As is shown in
Figure 3A and C, both TO901317 and GW3965 successfully
upregulated the mRNA expression of LXRα-targeted lipo-
genic genes, such as SREBP-1c, FAS, ChREBP and ACC.
Moreover, miR-613 significantly decreased LXRα-induced
expression of those genes (Figure 3B and D). Furthermore,
miR-613 also downregulated these TO901317-induced tar-
get genes in L02 cells (Additional file 2: Figure S2). To
examine whether miR-613 repressed lipogenic genes via
downregulation of LXRα, HepG2 cells were cotransfected
with miR-613 mimic and LXRα-expressing plasmid pEX-
LXRα (without 30-UTR in LXRα mRNA). As expected, ec-
topic expression of LXRα reversed the inhibitory effect of
miR-613 on lipogenic genes (Figure 4). These resultsFigure 4 MiR-613 represses lipogenic genes by mediating LXRα. HepG
LXRα-expressing plasmid pEX-LXRα (without 30-UTR in LXRα mRNA) for 24
normalized to β-actin mRNA expression, respectively. The relative level of
*, P < 0.05 (n = 3 for each group).suggested that miR-613 repressed lipogenic genes in an
LXRα-dependent manner.MiR-613 reduces lipid droplet accumulation through
downregulation of LXRα in HepG2 cells
To further investigate the function of miR-613, we deter-
mined whether miR-613 could decrease LXRα-induced
accumulation of lipid droplets in HepG2 cells. 12 hours
after transfected with miR-613 mimic, HepG2 cells were
treated with TO901317 for 24 hours, then Oil Red O
staining was performed. The lipid droplet accumulation
of cells transfected with miR-613 mimic was markedly
reduced compared with negative controls (Figure 5A).
However, ectopic expression of LXRα (without 30-UTR)
attenuated the suppression of lipid droplet accumulation
by miR-613 (Figure 5B). These results suggested that
miR-613 might function as an anti-lipogenesis miRNA in
HepG2 cells.2 cells were cotransfected with 80 nM miR-613 mimic or NC and
hours. The SREBP-1c, FAS, ChREBP and ACC expression was
indicated gene expression determined using the 2-△△CT method.
Figure 5 MiR-613 represses lipogenesis by mediating LXRα. The lipid synthesis was shown by Oil Red O staining (400×). A: After 12 hours
transfected with 80 nM miR-613 mimic or NC, HepG2 cells were treated with TO901317 (5 μM) or GW3965 (2 μM) for 24 hours. B: HepG2 cells
were cotransfected with 80 nM miR-613 mimic or NC and LXRα-expressing plasmid pEX-LXRα for 24 hours. Results represent 3 independent
experiments.
Zhong et al. Lipids in Health and Disease 2013, 12:32 Page 7 of 9
http://www.lipidworld.com/content/12/1/32Discussion
With the development of our modern society, the peo-
ple’s lifestyle is characterized by an overabundant supply
of food rich in energy and little physical activity, which
enhance the lipid accumulation leading to a series of
lipogenesis-associated diseases including dyslipidemia,
hypertension, heart disease and fatty liver [15-18].
Therefore, the negative regulation of lipid synthesis may
help with the treatment for lipid metabolism disorders.
In our present study, we found miR-613 as an anti-
lipogenesis miRNA through the suppression of LXRα,
which provided a novel effective target for the therapy of
lipogenesis-associated diseases.
From the recent studies, our understanding of miR-
613 is extremely limited. It is reported that miR-613 is
involved in the auto-regulation of LXRα by directly
targeting LXRα 30-UTR, but its biological function isn’t
mentioned. Here, we first revealed the anti-lipogenic
function of miR-613. It repressed expression of lipogenic
genes and accumulation of lipid droplets in HepG2 cells
by suppression of LXRα, which suggested the potential
use of miR-613 as a therapeutic tool in lipogenesis-
associated diseases, such as hepatic steatosis. Another
report has demonstrated that miR-613 has inhibitory ef-
fect on the activity of the Wnt pathway by targeting the
pathway upstream of Axin or active β-catenin. However,
there is no evidence showing the effect of miR-613 on
Wnt-dependent human cancer cells and the precise and
direct targets of miR-613 [7,8]. Consequently, both the
effects of miR-613 on Wnt-dependent cell proliferationand its other biological functions remain to be clarified.
Moreover, for one miRNA can target more than one
gene, further studies are needed to establish target land-
scape of miR-613.
MiRNAs regulate gene expression by binding mRNAs
at 30-UTR/50-UTR or open reading frame (ORF), leading
to translational repression and mRNA cleavage [19-21].
Though the targeting site for miR-613 at LXRα 30-UTR
has been uncovered, further study is needed to find
out whether miR-613 can regulate LXRα by binding at
50-UTR or ORF of LXRα mRNA. Unfortunately, bioinfor-
matic analysis showed no possible binding site for miR-613
at ORF of LXRα mRNA, which might not be the mechan-
ism by which miR-613 regulates LXRα.
Increasing genes are shown to be in the control of
LXRα, but the regulation of LXRα itself is not fully
understood. It has been reported that peroxisome
proliferator-activated receptor (PPAR), retinoid-related
orphan receptor (ROR), protein kinase C (PKC) and
oxysterol binding protein related protein 1S (ORP1S) can
potentially regulate the activation of LXRα [22-25]. In
addition, the epigenic modification such as phosphory-
lation and SUMOylation, may affect LXRα actions [26,27].
Thus there are opportunities for miR-613 to indirectly
regulate LXRα through the modulation of its upstream
regulators such as PPAR, ROR and PKC. Similarly,
although we demonstrated that miR-613 indirectly af-
fected the expression of lipogenic genes, it needs to be ex-
amined whether the miRNA could directly target these
lipogenic genes.
Zhong et al. Lipids in Health and Disease 2013, 12:32 Page 8 of 9
http://www.lipidworld.com/content/12/1/32Conclusions
In our present study, we demonstrated that miR-613
function as a novel modulater participating in lipid
metabolism. It repressed lipogenic genes including
SREBP-1c, FAS, ChREBP and ACC by suppression of
LXRα expression. Subsequently, the accumulation of
lipid droplets in HpG2 cells was significantly decreased
by miR-613. These findings suggested that miR-613
was a potential target for the therapy of lipid dysfunc-
tion associated diseases.
Additional files
Additional file 1: Figure S1. MiR-613 decreases TO901317-activated
LXRα expression at both mRNA and protien levels in L02 cells. 12 hours
after transfected with 80 nM miR-613 mimic or NC, L02 cells were treated
with TO901317 (5 μM) for 24 hours. Real-time PCR analysis for LXRα
mRNA level (A) and Western blot analysis for LXRα protein level (B). The
relative level of LXRα expression determined using the 2-△△CT method. *,
P < 0.05 (n = 3 for each group).
Additional file 2: Figure S2. MiR-613 suppresses LXRα-induced
lipogenic genes in L02 cells. A, L02 cells were treated with TO901317
(5 μM) for 24 hours. Real-time PCR analysis for SREBP-1c, FAS, ChREBP
and ACC mRNA level. B, after 12 hours transfected with 80 nM miR-613
mimic or NC, L02 cells were treated with TO901317 (5 μM) for 24 hours.
Real-time PCR analysis for SREBP-1c, FAS, ChREBP and ACC mRNA level.
The relative level of lipogenic gene expression determined using the
2-△△CT method. *, P < 0.05 (n = 3 for each group).
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